Black Diamond Therapeutics, Inc. Share Price OTC Markets
Stocks
BDTX
US09203E1055
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
OTC Markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | - |
| Market Cap | 122M 105M 98.61M 90.08M 169M 11.5B 169M 1.17B 452M 5.9B 457M 447M 19.01B | P/E 2026 * |
-3.44x | P/E 2027 * | -2.23x |
|---|---|---|---|---|---|
| Enterprise Value | 122M 105M 98.61M 90.08M 169M 11.5B 169M 1.17B 452M 5.9B 457M 447M 19.01B | EV / Sales 2026 * |
19.5x | EV / Sales 2027 * | - |
| Free-Float |
99.35% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Velleca
CEO | Chief Executive Officer | 62 | 15/09/2023 |
Elizabeth Buck
CTO | Chief Tech/Sci/R&D Officer | 51 | 10/08/2021 |
Erika Jones
DFI | Director of Finance/CFO | 41 | 06/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Garry Menzel
BRD | Director/Board Member | 61 | 28/02/2017 |
Samarth Kulkarni
BRD | Director/Board Member | 47 | 30/11/2019 |
Ali Behbahani
BRD | Director/Board Member | 49 | 30/11/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 122M | |
| -1.79% | -2.27% | +43.23% | +99.78% | 67.98B | |
| -0.94% | +1.26% | +36.74% | +85.02% | 64.94B | |
| -0.31% | +6.54% | -12.96% | +377.83% | 27.58B | |
| +0.86% | +1.65% | -7.74% | -13.58% | 26.06B | |
| -0.98% | -0.25% | +24.99% | +16.42% | 25.74B | |
| -0.42% | +0.42% | +23.61% | -16.76% | 20.09B | |
| -2.96% | -15.21% | +216.20% | +375.70% | 17.16B | |
| +0.90% | -0.64% | -6.17% | +554.30% | 14.92B | |
| -0.20% | +8.37% | +55.78% | +165.57% | 14.62B | |
| Average | -0.55% | +0.26% | +41.52% | +182.70% | 31.01B | |
| Weighted average by Cap. | -0.82% | +0.18% | +36.96% | +141.86% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.25M 5.38M 5.06M 4.62M 8.65M 590M 8.67M 59.79M 23.2M 303M 23.47M 22.96M 975M | - |
| Net income | -36.96M -31.81M -29.93M -27.34M -51.14M -3.49B -51.28M -354M -137M -1.79B -139M -136M -5.77B | -64.65M -55.63M -52.34M -47.81M -89.44M -6.1B -89.69M -618M -240M -3.13B -243M -237M -10.09B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BDTX Stock
- BDTX Stock
Select your edition
All financial news and data tailored to specific country editions
